Background and Objectives Long-acting injectable antiretrovirals represent a pharmacological alternative to oral formulations and an innovative clinical option to address adherence and reduce drug costs. Clinical studies in children and adolescents are characterised by ethical and logistic barriers complicating the identification of dose optimisation.
Introduction
Human immunodeficiency virus (HIV) is one of the leading causes of death that is treated as a global priority. Initiation of highly active antiretroviral therapy has saved millions of lives in the past decade [1] . However, adherence to antiretroviral therapy continues to be one of the major issues hindering treatment efficacy and suboptimal adherence can vary considerably in patients from 50 to 70% in the clinical setting [2] . Currently available formulations necessitate lifelong daily dosing and poor adherence has been attributed to numerous factors including pill fatigue, side effects and a range of socioeconomic considerations associated with different populations [3] . Problems can be particularly exacerbated in specific sub-populations of patients such as paediatric patients, where drug administration is additionally influenced by the caregiver, the family or the social environment [4] .
Long-acting injectable (LAI) formulations have the potential of solving the adherence issues related to oral (PO) formulations, reducing the amount of antiretroviral (ARV) used for the therapy and consequently the cost of therapy. The use of LAI formulations in paediatric patients has already been hypothesised in different disease areas and the use of LAI antipsychotics has been recently described in adolescents [5] [6] [7] .
Two LAI ARV formulations have recently been developed and several others are currently under investigation [1] . Rilpivirine and cabotegravir, owing to their long halflives and potency, have been selected for monthly and quarterly long-acting administration, respectively [1, 8] . Clinical studies investigating the combination of cabotegravir and rilpivirine LAI formulations are currently ongoing to assess their safety and efficacy in adults [9] . Recent clinical trials (LATTE and LATTE-2) conducted in HIV-infected adults show that the cabotegravir and rilpivirine combination is safe and efficacious, which provides similar antiviral activity to efavirenz plus the nucleoside reverse transcriptase inhibitors tenofovir and emtricitabine [10] . The combination of rilpivirine and cabotegravir has the potential of being the first long-acting antiretroviral regimen that will not require a daily PO dose of any companion drugs, representing a pivotal achievement in the antiretroviral pharmacology. However, the identification of safe and effective dosing strategies for paediatric patients is complicated by multiple factors. Differences in anatomical and physiological characteristics of children and adolescents compared with adults have a relevant effect on the absorption, distribution, metabolism and excretion processes and are not correctly captured through traditional allometric scaling approaches [11] . Additionally, logistic and ethical challenges in designing dose finding/optimisation studies have limited medical guidance [12] .
Physiologically-based pharmacokinetic (PBPK) modelling represents a valuable tool to optimise doses prior to clinical trials in paediatric patients, thus minimising the time and cost invested in optimising doses. Physiologically based pharmacokinetic modelling is the mathematical description of anatomical, physiological and molecular processes defining pharmacokinetics. Compared with techniques usually used to select paediatric doses of adult formulations [13] [14] [15] [16] , PBPK modelling is a bottom-up approach integrating in vitro data, such as apparent intestinal permeability, intrinsic clearance and protein binding, in a mathematical description of absorption, distribution, metabolism and excretion to predict in vivo pharmacokinetics [17] .
Previous studies identified trough concentrations of 1.2 lg/mL and 17 ng/mL for cabotegravir and rilpivirine, respectively, need to be achieved to warrant efficacy [18, 19] . No toxicity limited concentrations have been reported previously [1] . Therefore, the aim of this study was to simulate the pharmacokinetics and inform optimal doses of LAI intramuscular (IM) formulations of cabotegravir and rilpivirine in 95% of children and adolescents aged 3-18 years through PBPK modelling for HIV treatment.
Methods
The PBPK models were constructed using Simbiology Ò Version 4.3.1, a product of Matlab Ò Version 8.2 (MathWorks, Natick, MA, USA). Instant and uniform distribution of drugs into tissues, no reabsorption of the drug from the large intestine and a blood-flow limited model [20] were assumed. A previously published adult IM PBPK model was used in this study [21] . The pharmacokinetics of LAI IM cabotegravir and rilpivirine were simulated and validated in adult PBPK models and later optimised for different weight categories of children (aged 3-12 years) and adolescents (aged 12-18 years). Children and adolescents between the ages of 3 and 18 years were divided into World Health Organization weight groups [22] and 100 virtual individuals were generated in each weight category.
Anatomy
Adult PBPK models were defined by key characteristics such as age and weight of the individuals. These defining characteristic values were further used for the computation of organ and tissue volumes, as well as blood flow rates through allometric equations described by Bosgra et al. [23] . The anatomy and physiology of children and adolescents were obtained from various literature sources, validated against available clinical data prior to dose optimisation [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . To improve the confidence of the constructed paediatric PBPK models, validation against intravenous lorazepam and intramuscular ceforanide as reference drugs was also conducted [34] . The various equations used for the construction of paediatric PBPK models and validations across different ages are available in the Electronic Supplementary Material.
Simulation of Absorption, Distribution, Metabolism and Excretion Processes
Drug diffusion from the IM compartment was assumed to obey first-order rate kinetics and the equation was obtained from Tegenge et al. [35] . The release rate of cabotegravir was obtained from the literature [36] and for rilpivirine, was derived using 48-week clinical data from LATTE-2, a recent phase II efficacy trial of these two formulations used in combination [19] . The intrinsic clearance values derived from in vitro data were obtained from the literature [37] and extrapolated to systemic clearance [38] . The distribution of the drug to different organs and tissues was simulated using previously published equations [21] .
Model Validation
The physicochemical properties of cabotegravir and rilpivirine used in the model are presented in Table 1 . The validation of the drug properties against clinical data was conducted in 100 virtual adults for a 800-mg quarterly dose of cabotegravir (from weeks 12-28) and for a subsequent monthly dose of 900 mg of rilpivirine (after the initial dose of 1200 mg) [1] . The release rate of rilpivirine was identified from the clinical data using the PBPK model [1] . The release rate was also validated against the LATTE-2 pharmacokinetic curve of cabotegravir and rilpivirine. The cabotegravir release rate was assumed to be 4.54 9 10 -4 h -1 as in LATTE-2 (or prior adult studies); however, there was a decrease in the release rate of rilpivirine from 9 9 10 -4 to 5 9 10 -4 h -1 , because the rilpivirine formulation included in LATTE-2 was different from a previous investigation and [19] with a slower release rate [1] . A schematic of the LATTE-2 dosing regimen implemented in this study is shown in Fig. 1 .
Dose Prediction
After the validation of the physicochemical parameters, the anatomy and physiology were modified to describe children and adolescents using appropriate allometric equations obtained from the literature, as described in the Electronic Supplementary Material [12, 23, [25] [26] [27] [28] 39] . Following the IM injection, dose optimisation in healthy paediatric individuals was conducted such that at least 95 out of the 100 virtual individuals had a mean trough concentration (C trough ) over the target trough concentrations for the required duration. Based on the LATTE-2 study, a target C trough of 1.35 lg/mL was used as the minimum target trough concentration for cabotegravir dose predictions following a 10-mg PO dose, and 70 ng/mL was used as the average concentration for rilpivirine following a 25-mg dose [19] . A PO dosing regimen for 4 weeks (steady state) followed by a loading dose and eleven maintenance doses for a 4-weekly IM administration of rilpivirine and cabotegravir were simulated, for a total period of 52 weeks. CL int intrinsic clearance, CYP cytochrome P450, Log P o:w partition coefficient between octanol and water, pKa logarithmic value of the dissociation constant, R blood-to-plasma drug ratio, UGT uridine diphosphate glucuronosyltransferase
Sensitivity Analysis
A differential sensitivity analysis was performed to identify the key parameters that impact the pharmacokinetic profiles of LA formulations [40] . Analysis was performed for the loading dose and the first maintenance dose of the cabotegravir and rilpivirine LAI IM formulation in adults. Sensitivity was analysed using the provided inbuilt feature of Simbiology at user-defined values without normalisation in the computation. Six parameters (blood-to-plasma ratio, cardiac output, plasma clearance, liver weight, fraction unbound and release rate) were analysed against drug plasma concentrations. Each parameter was varied by 20% from its mean value and 100 simulations were conducted while keeping the rest of the parameters constant. The sensitivity coefficient (/ i ) indicates the change of plasma concentration values (Y) with respect to a unit change in a parameter (X) as shown in Eq. (1) [40] :
Results
The structure and equation of the current PBPK model are based on a previous publication and modified to represent antiretroviral distribution in paediatric and adolescent individuals [21] . The anatomy and physiology of children and adolescents were also validated against the literature and the results are presented in the Electronic Supplementary Material. Physiologically-based pharmacokinetic models were initially qualified by validation against available clinical data for both cabotegravir and rilpivirine in adults to ensure that the selected drug properties were appropriate. The mean simulated pharmacokinetic parameters for maximum plasma concentration (C max ), C trough and area under the plasma concentration-time curve (AUC) were compared against available clinical data for the LA formulations for both drugs used in adults (cabotegravir, second IM dose of 800 mg and rilpivirine 900 mg after the initial dose of 1200 mg) [shown in Table 2 ; Fig. 2] . A stringent qualification of accuracy was applied whereby PBPK models were considered validated only if the mean value was within 0.5-fold from the clinical Fig. 1 Validation of adult physiologically-based pharmacokinetic model using the LATTE-2 dosing regimen. Oral dosing regimen was followed for 4 weeks, followed by a single 4-weekly intramuscular (IM) dose and 11 4-weekly intramuscular maintenance doses. CAB cabotegravir, QD once daily, Q4W 4-weekly dose, RPV rilpivirine Values are represented as geometric mean AUC area under the plasma concentration-time curve, C max maximum plasma concentration, C trough trough plasma concentration, % CV coefficient of variation expressed as a percentage a For cabotegravir, C max and C trough are lg/mL and AUC is lg 9 h/mL at day 84 value, rather than the conventional two-fold agreement limits [41] . The formulation characteristics were maintained equal to the adult formulation for the simulations in children and adolescents, assuming a similar release rate of the drugs from the formulations, and the use of the same formulations in adults, children and adolescents. Intramuscular doses were optimised to have a pharmacokinetic profile with the concentration exceeding the 10 mg PO C trough for cabotegravir over the duration of treatment and an average concentration over the C trough of 25 mg PO rilpivirine for the first 12 IM doses (Fig. 3) . For rilpivirine, it was also ensured that the concentrations were always above the 90% protein-bindingadjusted inhibitory concentration (PAIC 90 ) value of 12.1 ng/ mL [18] subsequent to the loading dose. A summary of predicted doses for both cabotegravir and rilpivirine for different weight categories is shown in Table 3 .
Cabotegravir
The validation for 800 mg of IM cabotegravir resulted in mean predicted AUC, C max and C trough values that were ?15.6, ?6.1 and ?9.1% compared with clinical values, respectively [1] . A target trough concentration of 1.35 lg/ mL (10 mg PO C trough ) was chosen from the literature [1] . The doses for different weight groups were informed such that at least 95 out of the 100 virtual individuals had a C trough value over the target trough concentration for a duration of 48 weeks (Fig. 4) . The daily PO dose administered for a period of 4 weeks was 10 mg for weights ranging between 14 and 50 kg and 20 mg for weights between 50 and 70 kg. For IM cabotegravir, the loading dose ranged between 200 and 600 mg and maintenance doses between 100 and 250 mg for the simulated plasma C trough to stay over the 10 mg PO C trough as described in Table 3 .
Rilpivirine
The simulated mean AUC, C max and C trough values were ?13.2, -6.5 and -8.8%, compared with the clinical data [1] . After the validation of the rilpivirine PBPK model, the first-order kinetic release rate was identified to be 9 9 10 -4 h -1 [1] . The validation was then performed to find the optimal release rate for rilpivirine pharmacokinetics from the LATTE-2 study. Because of the Fig. 2 Validation of the physiologically-based pharmacokinetic model parameters against clinical data for the second intramuscular administration in adults. a Cabotegravir (800 mg followed by 800 mg quarterly). b Rilpivirine (1200 mg followed by 900 mg monthly) [1] . SD standard deviation Fig. 3 Validation of the release rate against clinical data from the 48-week LATTE-2 study in adults. a cabotegravir and b rilpivirine [19] . The target trough concentration is 1.35 lg/mL for cabotegravir and 12 ng/mL for rilpivirine. SD standard deviation reformulation of rilpivirine, the optimal release rate was observed to be 5 9 10 -4 h -1 . The optimal doses were informed for different weight categories such that the average drug C trough plasma concentrations of 48 weeks remained over 70 ng/mL (25 mg PO C trough ) [19] . A fixed daily PO dose of 25 mg was administered for 4 weeks prior to IM doses. The loading dose ranged from 250 to 550 mg and the maintenance doses from 200 to 500 mg across weight groups from 15-to 70-kg individuals. The optimal doses ensured plasma concentrations over the PAIC 90 value and average IM concentrations over 25 mg PO C trough for at least 95 out of 100 individuals (Fig. 5 ). Figure 6 shows the mean differential sensitivity analysis plot of 100 runs for six chosen parameters with respect to time. The analysis was performed for two successive (loading and maintenance) monthly IM doses of cabotegravir and rilpivirine in adults.
Sensitivity Analysis
For cabotegravir, the analysis indicated that the plasma concentration is sensitive to only two of the six factors and a higher influence was observed in the first days following administration. Cardiac output and systemic clearance of the drug had higher sensitivity towards the variation in plasma concentrations. Protein binding, release rate, liver weight and blood-to-plasma ratio were negligibly sensitive. This indicates that physiological factors and the UGT content in the liver had a higher potential to influence the simulated pharmacokinetics. Sensitivity against cardiac output was negative for most of the duration, indicating an increased effect against plasma concentration even when the value changes by ±20% from the mean. Sensitivity against systemic clearance had a similar trend to cardiac output but with lower intensity. During the initial days after the administration of the maintenance dose, both these factors showed a positive relationship against plasma concentration, indicating a lower effect.
For rilpivirine, the change in plasma concentration was not sensitive when cardiac output, liver weight and release rate varied ±20% from the mean. Blood-to-plasma ratio had a higher positive effect immediately after dosing, implying a lower influence on plasma concentration. Blood-to-plasma ratio and systemic clearance showed a positive relationship over the entire dosing period, indicating a decreased effect against plasma concentration. Protein binding fluctuated between positive and negative; however, the variation is minimal, signifying minimal or no effect on plasma concentration.
Discussion
Optimal treatment adherence is essential for the effective inhibition of viral replication and to mitigate development of resistance to ARVs. Although PO formulations have been demonstrated to result in therapeutic concentrations, sub-optimal adherence in patients who are receiving PO daily dosing for treatment and prevention have been described [2, [42] [43] [44] [45] . Alternative administration strategies could support higher adherence, reducing the frequency of administration and addressing pill fatigue. More specifically, formulations allowing a monthly or quarterly administration could address the adherence issue, thus 70 (25 mg PO C trough ) [19] 1370 (10 mg PO C trough ) [19] C trough trough concentration decreasing the risk of drug resistance. Antiretrovirals with high potency and favourable pharmacokinetics are essential for the development of the LAI strategy. The recent development of novel formulations of cabotegravir and rilpivirine constitutes a remarkable step towards the definition of LAI strategies, providing innovative pharmacological tools for adults [1] . Dose optimisation in special populations of patients such as children and adolescents is complex owing to their unique physiological and anatomical characteristics compared with adults. Traditionally, clinical trials have not been frequently conducted in these patient populations because of ethical and logistical considerations [46] . However, recent regulations promote clinical studies in paediatric patients to evaluate safety and efficacy prior to therapy [47, 48] . The present study focuses on the identification of dosing strategies of cabotegravir and rilpivirine in children and adolescents using computational pharmacokinetic modelling for HIV treatment.
Various PBPK models have been developed for adults, and recently, this modelling technique has also been used for a variety of special populations including children and adolescents [32, 49] . Drug distribution can be simulated in special populations of patients through the integration of age-related anatomical and physiological changes into the mathematical PBPK framework. Physiologically-based pharmacokinetic modelling has been recently used for the prediction of midazolam and theophylline in neonates, infants and children [12] . In two other studies, the relationship between adult and paediatric clearance rates was established using the cytochrome P450 ontogeny for six compounds and then simulations were performed for five different drugs at different age groups [50, 51] . An oseltamivir PBPK model was used to predict the pharmacokinetics in neonates and infants with influenza [52] and a disease-specific model was also recently developed in children with and without liver cirrhosis [53] . Both cabotegravir and rilpivirine are characterised by long-half lives and physicochemical properties that are compatible with nanoformulations for LAIs, representing attractive options for continuous therapy [1, 54] . Using physiochemical properties and in vitro data, the pharmacokinetics of cabotegravir and rilpivirine in adults was validated against available clinical data. The model validation was conducted at the second dose of the LAI ARVs to have a mathematical representation of the pharmacokinetics at steady state. Low accuracy and precision were observed in the É CLAIR study where the simulated C trough value of cabotegravir was 1.35 lg/mL compared with the observed value, which was less than 0.66 lg/mL (4*PAIC 90 ) [55] . Hence, stringent guidelines were applied for the validation process where ±50% deviation from the mean clinical values was considered acceptable instead of the conventional two-fold deviation [41] . The pharmacokinetic parameters AUC, C max and C trough simulated through the PBPK approach were in agreement with the clinical data and, therefore, our PBPK model was considered robust for predicting the LAI IM doses in children and adolescents. In the simulation of LAI pharmacokinetics in children, the release rates of the LAI formulations were maintained equal to the validation in adults, to facilitate bridging to a paediatric simulation. Although the physiology of the muscular tissues is different between adults and children, this could potentially support the use of the existing formulations in paediatric clinical studies with no further reformulation [56] . However additional studies are required because there is a possibility that smaller doses with less injection volume could decrease the total surface area and strain in the muscle, thereby altering the pharmacokinetic profile. The doses were optimised such that cabotegravir and rilpivirine concentrations were over the target trough concentrations (described in Sect. 2) for the duration of the dose. Although PAIC 90 values indicate a trough concentration to suppress the virus in vitro, this does not translate into effective therapeutic activity in vivo [57] . Concentration data were derived from optimized dosing strategies calculated for each weight band, as described in Sect. 3. SD standard deviation Therefore, the dose optimisation was conducted considering LATTE-2 study target trough concentrations.
The required dose was proportional to the weight of the individual, which indicates increases in the volume of distribution and systemic clearance in adolescents. As the weight of the individual increased from 15 to 70 kg, the required dose of cabotegravir tripled in an individual weighing 70 kg compared with a 15-kg individual, whereas the dose needed was just over double in the case of rilpivirine. Fluctuation in maximum and trough plasma concentration of cabotegravir is [2 lg/mL compared with rilpivirine (\100 ng/mL). Additionally, cabotegravir is more sensitive to variations in clearance and cardiac output compared with rilpivirine (as shown in Fig. 6 ) and because of these physiological variations across weight groups, a higher dose is required in the case of cabotegravir for adolescents compared with children. This indicates that doses cannot be linearly extrapolated based on weight and a deeper understanding of important mechanistic processes influencing the pharmacokinetics in children and adolescents is required. The loading doses are higher compared with the maintenance doses as the extra dose is essential to maintain drug plasma concentrations over the C trough / PAIC 90 values. Because the maintenance dose for cabotegravir is low compared with rilpivirine, they could be more suitable for a less frequent (bimonthly or quarterly) administration.
Long-acting injectable formulations may improve the problems faced with low adherence of therapies in children and adolescents. The identification of optimal doses in healthy paediatric individuals should be given priority as most of the doses for prescribed drugs are simply scaled from adult doses with varying success. However, pain involved during the administration of IM injections has the potential to refrain children from preferring this route and opting for PO dosing regimens. Chloramphenicol dose scaling from adults in neonates and infants reached toxic concentrations, which led to a higher mortality rate, an example of where the developmental pharmacology of paediatric patients was ignored [58] . The mortality rate was high in neonates affected with kernicterus who were administered penicillin/sulfisoxazole than with oxytetracycline in an another case [59] . In both these cases, an immature glucuronidation system led to the accumulation of the drug, resulting in high plasma concentrations and conclusively demonstrating that the physiological processes of the child cannot always be accounted for by scaling adult doses [59, 60] .
Although the simulated doses for children and adolescents could represent a valuable guideline for drug safety and efficacy clinical studies, the applied modelling strategies have some limitations. Numerous barriers can complicate the implementation of dosing recommendations for special populations. Because anatomical and physiological changes in children follow a non-linear trend, pharmacokinetic and pharmacodynamic investigations need to be conducted to evaluate the safety, efficacy and tolerability profiles in children and the current modelling approach can support a rational identification of suitable dosing strategies [61] . Especially in infants and neonates aged younger than 3 years, the ontogeny of cytochrome P450 expression in the liver and wide variation in organ weights and volumes could lead to low accuracy in model prediction and hence this study focuses on children aged older than 3 years. Some anatomical and physiological features and the associated complex biological processes have not been simulated owing to a paucity of relevant data [35] . Absence of information on drug transporters at the injection site could alter the absorption, distribution and metabolic processes, which could not be captured in the current PBPK model. Evidence suggests that cabotegravir undergoes enterohepatic recirculation; however, quantitative evaluation of this physiological process is absent and hence could not be incorporated in the PBPK model [62] . Recent investigation with a paliperidone LAI micro-suspension revealed formation of a granuloma as a result of macrophage accumulation surrounding the site of injection. This phenomenon further controlled drug release from the depot Fig. 6 Differential sensitivity analysis of plasma concentration against key parameters (blood-plasma ratio, cardiac output, fraction unbound, liver weight, release rate and systemic clearance) in adults for the 4-weekly intramuscular loading dose and the first maintenance dose. a cabotegravir and b rilpivirine and evidence also showed drug uptake and release from macrophages [63] . The extent of the occurrence of this phenomenon and the size of the depot could alter the release rates and thereby drug pharmacokinetics, which was not accounted for in this study. Physiological and metabolic variation of muscle composition in children compared with adults was not accounted for during the dose optimisation process [56] . Low clinical C max compared with the simulated pharmacokinetic curve (Fig. 2) could be owing to the fraction of drug distributed through the lymphatic circulation. Additionally, the potential adverse effects considering the differences in the anatomy and physiology of children compared with adults, prolonged exposure and the inability to discontinue therapy once administered are important factors to be assessed before drug administration [3] .
Long-acting injectable therapy has attracted considerable attention in various therapeutic areas, including chronic HIV infection. For example, the National Institutes of Health recently provided support to set up a worldwide team involving researchers from academia and the pharmaceutical industry to facilitate the development of LAI formulations for HIV. This Long-Acting/Extended Release Antiretroviral Resource Program (LEAP; http://www. longactinghiv.org) includes a PBPK modelling service to facilitate the design of long-acting formulations for HIV and related infectious diseases. This type of support may improve the efficiency of the selection of formulations, doses and dose intervals for paediatric and other special populations.
Conclusion
Physiologically-based pharmacokinetic models were successfully validated for both cabotegravir and rilpivirine LAI formulations against available clinical data in adults. A novel PBPK model for the prediction of pharmacokinetics in children and adolescent was developed to simulate dose selection in this vulnerable group. Dosing strategies for cabotegravir and rilpivirine were estimated in different weight groups of children and adolescents considering two efficacy target trough concentrations. From this modelling study, the predicted paediatric dosing of caboteravir and rilpivirine differs for each weight category and scaling adult doses could have led to plasma concentrations either below the PAIC 90 /Minimum Effective Concentration value or above a safe level. Different dosing fractions compared with adult dosages for cabotegravir and rilpivirine indicate that drug-specific physiocochemical parameters and absorption, distribution, metabolism and excretion characteristics play a key role in controlling the pharmacokinetics. Physiologically-based pharmacokinetic predictions from this study could potentially inform reference doses required to conduct paediatric clinical trials for various weight categories.
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